Developing therapeutics for Alzheimer's disease : progress and challenges
Author(s)
Bibliographic Information
Developing therapeutics for Alzheimer's disease : progress and challenges
Academic Press, c2016
- : hbk
Available at 1 libraries
  Aomori
  Iwate
  Miyagi
  Akita
  Yamagata
  Fukushima
  Ibaraki
  Tochigi
  Gunma
  Saitama
  Chiba
  Tokyo
  Kanagawa
  Niigata
  Toyama
  Ishikawa
  Fukui
  Yamanashi
  Nagano
  Gifu
  Shizuoka
  Aichi
  Mie
  Shiga
  Kyoto
  Osaka
  Hyogo
  Nara
  Wakayama
  Tottori
  Shimane
  Okayama
  Hiroshima
  Yamaguchi
  Tokushima
  Kagawa
  Ehime
  Kochi
  Fukuoka
  Saga
  Nagasaki
  Kumamoto
  Oita
  Miyazaki
  Kagoshima
  Okinawa
  Korea
  China
  Thailand
  United Kingdom
  Germany
  Switzerland
  France
  Belgium
  Netherlands
  Sweden
  Norway
  United States of America
Description and Table of Contents
Description
Developing Therapeutics for Alzheimer's Disease: Progress and Challenges provides a thorough overview of the latest advances toward the development of therapeutics for Alzheimer's disease, along with the major hurdles that still must be overcome and potential solutions to these problems. Despite the lack of progress toward developing therapeutics that can slow or stop the progression of this disease, important discoveries have been made and many promising approaches are advancing in preclinical studies and clinical trials. This book outlines the special challenges related to specific targets and approaches, while presenting a realistic, comprehensive and balanced view of drug discovery and development in this area.
Written by international leaders in the field, the book assesses prospects for the emergence of effective agents and allows readers to better understand the challenges, failures, and future potential for research in Alzheimer's disease. This book is a valuable resource to academic scientists carrying out translational research in Alzheimer's disease, industrial scientists engaged in Alzheimer's drug discovery, executives in biopharmaceutical companies making strategic decisions regarding the direction of internal research and potential outside partnerships, and graduate-level students pursuing courses on Alzheimer's therapeutics.
Table of Contents
1. The Complex Pathways to Mechanism-Based Therapeutics in Alzheimer's Disease
2. The Genetic Basis of Alzheimer's Disease
3. B-Secretase Inhibition
4. Y-Secretase Inhibitors: from Chemical Probes to Drug Development
5. Therapeutic Targeting of AB42
6. Modulators of Amyloid B-Protein (AB) Self-Assembly
7. Anti-Amyloid-B Immunotherapy for Alzheimer's Disease
8. Targeting AB Receptors to Modify Alzheimer's Disease Progression
9. Blood-Brain Barrier Transport of Alzheimer's Amyloid B-Peptide
10. Alzheimer's Disease Therapeutics Targeting Apolipoprotein E
11. Microtubule Stabilization
12. Tau Phosphorylation as a Therapeutic Target in Alzheimer's Disease
13. Stimulation of Tau Degradation
14. Passive Immunotherapy for Tau Pathology
15. Inhibition of Tau Aggregation as a Basis for Treatment and Prevention of Alzheimer's Disease
16. Neuroprotective Strategies for Alzheimer's Disease Prevention and Therapy
17. Symptomatic Cognitive Enhancing Agents
18. Tackling Alzheimer's Disease by Targeting Oxidative Stress and Mitochondria
19. Preclinical and Clinical Issues in Alzheimer Drug Development
20. Molecular Imaging in Alzheimer Clinical Trials
21. Fluid Biomarkers and Diagnostics
22. Non-Pharmacologic Activity Interventions to Prevent Alzheimer's Disease
23. Prospects and Challenges for Alzheimer Therapeutics
by "Nielsen BookData"